Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
IL-2/IL-15R beta/gamma
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05092360IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease)A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)AZ, CA, FL, NJ, NY, NC, OH, OR, SC, SD, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04592653IIRecurrent ovarian cancerClinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3MI, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04009681I/IIAdvanced solid tumorsAn Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid TumorsAZ, CO, FL, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
anti-EGFR AbEGFR antagonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SAR444245pegylated recombinant IL-2 variant THOR-707, THOR-707IL-2/IL-15R beta and gamma agonistClinical Trials
NCT05086692I/IIAdvanced solid tumorsA Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid TumorsCA, FL, GAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MDNA11IL-2/IL-15R beta and gamma agonistClinical Trials
PD-1iBlocks PD-L1/2 inhibition of T cells
PD-L1iBlocks PD-L1 inhibition of T cells
NCT04455620I/IIAdvanced solid tumorsPhase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid TumorsCT, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BNT151IL-2/IL-15R beta and gamma agonistClinical Trials
NCT05267626I/IIAdvanced solid tumorsA Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerFL, MI, NC, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
AU-007IL-2/IL-15R beta and gamma agonistClinical Trials
NCT05081609I/IIAdvanced solid tumorsIL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesMA, NC, OH, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TransCon IL-2 β/γIL-2/IL-15R beta and gamma agonistClinical Trials
NCT04234113I/IbAdvanced solid tumors (in expansion)A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid TumorsCT, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SOT101SO-C101, IL-15/IL-15 receptor alpha sushi+ domain fusion protein SO-C101, RLI 15, interleukin-15/interleukin-15 receptor alpha sushi+ domain fusion protein SO-C101IL-2/IL-15R beta and gamma agonistClinical Trials
NCT04294576IAdvanced solid tumors with dMMR, high MSI or high TMBFirst-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid TumorsMO, NY, SC, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BJ-001Interleukin-15 fusion protein BJ-001Directs IL-15 mediated immune cell stimulation to alpha v beta3,5,6+ tumor cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05382325IAdvanced solid tumors (inc expansion)A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid TumorsSD, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MK-1484IL-2/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04261439IAdvanced solid tumors that progressed after a previous response to PD-1/PD-L1 and/or CTLA-4 inhibitor therapy - subcutaneous injectionA Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and LymphomaCA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NIZ985hetIL-15, IL15/sIL-15R alphaIL-2/IL-15R beta and gamma agonistClinical Trials
Spartalizumabanti-PD-1 monoclonal antibody PDR001, PDR001Blocks PD-L1/2 inhibition of T cellsClinical Trials
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317, BGB-A317Blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT05360680IAdvanced WT-1+ solid tumors (inc ovarian expansion)A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic CancersNC, OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CUE-102WT1-targeted IL-2-based fusion protein CUE-102Immune response against cancer expressing WT1Clinical Trials
NCT04710043IAdvanced solid tumors (inc expansion)Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid TumorsCT, IL, NC, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BNT152ribocytokine IL-7 BNT152, human interleukin-7 mRNA-encoded BNT152IL-7R agonistClinical Trials
BNT153IL-2/IL-15R beta and gamma agonistClinical Trials
NCT05052268IAdvanced solid tumors (inc expansion)A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid TumorsCA, IA, MA, MN, NC, OH, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
XTX202IL-2/IL-15R beta and gamma agonistClinical Trials
NCT04250155IAdvanced solid tumors (inc expansion)A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid TumorsCA, CT, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
XmAb24306interleukin-15/interleukin-15 receptor alpha complex-Fc fusion protein XmAb24306, IL15/IL15R alpha heterodimeric Fc-fusionsIL-2/IL-15R beta and gamma agonistClinical Trials
NCT04659629IAdvanced solid tumors (inc expansion)A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory CancerAZ, CA, FL, MN, NY, OR, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NL-201IL-2R alpha-independent IL-2/IL-15 AgonistIL-2/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.